SCHEMBL8235348

SCHEMBL8235348

CC(=O)C(C)n1nc(-c2ccc(Cl)cc2)n(C2CC2)c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR2 P30518 2/20 0.37
AVPR1A P37288 2/20 0.37
LMNA P02545 3/20 0.37
CNR1 P21554 5/20 0.37
CNR2 P34972 3/20 0.36
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
HIF1A Q16665 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MAT2A P31153 1/20 0.34
MDM2 Q00987 1/20 0.34
HSD11B1 P28845 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4498779 0.90 KDM4E (0.38) AVPR2AVPR1ALMNACNR1CNR2
SCHEMBL3976537 0.86 LMNA (0.44) LMNAALDH1A1GLAHPGDMAPK1
SCHEMBL4499313 0.81 KDM4E (0.43) AVPR2AVPR1ALMNACNR1CNR2
SCHEMBL8235916 0.78 AVPR2 (0.39) AVPR2AVPR1ALMNACNR1CNR2
SCHEMBL8739481 0.77 AVPR2 (0.44) AVPR2AVPR1ALMNACNR1CNR2
SCHEMBL8233102 0.77 METAP2 (0.42)
SCHEMBL4504006 0.77 METAP2 (0.42)
SCHEMBL4487247 0.77 METAP2 (0.42)
SCHEMBL8235532 0.76 ALDH1A1 (0.42) LMNAALDH1A1CYP1A2HPGDHSD17B10
SCHEMBL8739503 0.75 AVPR2 (0.48) AVPR2AVPR1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2027096-B1 SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS Bayer Pharma AG (DE) 2012-05-23 EP disclosed
WO-2007134862-A1 SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS BAYER HEALTHCARE AG (DE) 2007-11-29 WO disclosed